Kineta Return on Tangible Equity 2014-2024 | KANT
Current and historical return on tangible equity values for Kineta (KANT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Kineta Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.02B |
$-0.01B |
1050.00% |
| 2024-03-31 |
$-0.02B |
$-0.01B |
-900.00% |
| 2023-12-31 |
$-0.01B |
$0.00B |
-400.00% |
| 2023-09-30 |
$-0.06B |
$0.00B |
-1450.00% |
| 2023-06-30 |
$-0.06B |
$0.01B |
-1311.11% |
| 2023-03-31 |
$-0.07B |
$0.00B |
-1444.44% |
| 2022-12-31 |
$-0.06B |
$0.01B |
-853.33% |
| 2022-09-30 |
$0.00B |
$0.01B |
0.00% |
| 2022-06-30 |
$-0.00B |
$0.01B |
-40.00% |
| 2022-03-31 |
$-0.01B |
$0.01B |
-43.84% |
| 2021-12-31 |
$-0.01B |
$-0.01B |
-43.64% |
| 2021-09-30 |
$-0.07B |
$0.03B |
-148.31% |
| 2021-06-30 |
$-0.06B |
$0.04B |
-135.52% |
| 2021-03-31 |
$-0.05B |
$0.05B |
-111.23% |
| 2020-12-31 |
$-0.05B |
$0.06B |
-104.71% |
| 2020-09-30 |
$0.00B |
$0.04B |
9.02% |
| 2020-06-30 |
$-0.00B |
$0.05B |
-9.64% |
| 2020-03-31 |
$-0.02B |
$0.05B |
-47.29% |
| 2019-12-31 |
$-0.03B |
$-0.00B |
-49.40% |
| 2019-09-30 |
$-0.06B |
$0.07B |
-69.75% |
| 2019-06-30 |
$-0.07B |
$0.08B |
-82.14% |
| 2019-03-31 |
$-0.06B |
$0.10B |
-82.58% |
| 2018-12-31 |
$-0.06B |
$0.11B |
-90.71% |
| 2018-09-30 |
$-0.06B |
$0.04B |
-101.79% |
| 2018-06-30 |
$-0.05B |
$0.06B |
-95.07% |
| 2018-03-31 |
$-0.06B |
$0.06B |
-100.92% |
| 2017-12-31 |
$-0.06B |
$0.07B |
-104.89% |
| 2017-09-30 |
$-0.06B |
$0.04B |
-92.83% |
| 2017-06-30 |
$-0.05B |
$0.05B |
-71.97% |
| 2017-03-31 |
$-0.04B |
$0.07B |
-65.43% |
| 2016-12-31 |
$-0.04B |
$0.08B |
-62.81% |
| 2016-09-30 |
$-0.04B |
$0.09B |
-84.85% |
| 2016-06-30 |
$-0.03B |
$0.03B |
-176.00% |
| 2016-03-31 |
$-0.02B |
$0.04B |
-218.18% |
| 2015-12-31 |
$-0.02B |
$0.00B |
-2300.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
